Literature DB >> 133117

Sex hormone binding globulin: the carrier protein for d-norgestrel.

A Victor, E Weiner, E D Johansson.   

Abstract

The binding of different synthetic steroids, used in hormonal contraception, to Sex Hormone Binding Globulin (SHBG) was studied by measuring their ability to displace tritiated testosterone from SHBG in a competitive protein binding system. Only 19-nortestosterone derivates had any significant ability to displace testosterone from SHBG, d-norgestrel (d-Ng) being the strongest displacer. Increasing the SHBG levels in women with previous constant plasma d-Ng levels increased these levels two- to sixfold. It is concluded that SHBG is the main carrier protein for d-Ng. The strong testosterone displacing activity of d-Ng might also explain androgenic side effects observed with d-Ng containig oral contraceptives.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 133117     DOI: 10.1210/jcem-43-1-244

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Levonorgestrel hormone releasing intrauterine system (Mirena) as a contraceptive in egg donors: case report.

Authors:  C Kailasam; V Akande; U D Gordon
Journal:  J Assist Reprod Genet       Date:  2005-03       Impact factor: 3.412

2.  Binding of levonorgestrel to monkey plasma proteins.

Authors:  A K Srivastava; S K Roy
Journal:  Experientia       Date:  1983-02-15

Review 3.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 4.  The third S.K. & F. Prize lecture, University of London, December 1981. The clinical pharmacology of oral contraceptive steroids.

Authors:  M L Orme
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

Review 5.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

6.  Jejunoileal bypass. Long-term results.

Authors:  C H Organ; M M Cegielski; B J Grabner; H E Keig; J A Saporta
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

7.  Testosterone-estradiol-binding globulin, unbound and total estradiol and testosterone, and total progesterone during the menstrual cycle in women with epilepsy taking antiepileptic drugs.

Authors:  C T Bäckström; R Södergård
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

8.  Binding capacity of testosterone-estradiol-binding globulin (TeBG), total and calculated unbound concentrations of testosterone in patients with carcinoma of the prostate treated with orchidectomy or estrogens.

Authors:  J E Damber; B Bergman; R Södergård; R Tomić
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

9.  Differences in oestrogen receptors in malignant and normal breast tissue as identified by the binding of a new synthetic progestogen.

Authors:  M J Iqbal; A A Colletta; S D Houmayoun-Valyani; M Baum
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.